Loading…
AstraZeneca's professional sales aid (US-68433) for BREZTRI AEROSPHERE contained false or misleading claims about the drug's efficacy, misbranding the product in violation of the Federal Food, Drug, and Cosmetic Act. The promotional communication created a misleading impression regarding the overall benefits patients could expect from Breztri treatment for chronic obstructive pulmonary disease maintenance therapy. The Office of Prescription Drug Promotion determined that the sales aid's violations raised public health concerns due to its misrepresentation of the drug's therapeutic benefits.